Moreover, we for the first time determined clinical implication of ZNF300 methylation in de novo MDS and AML patients, and found that ZNF300 methylation was a potential biomarker helpful for diagnosis in AML. The gene discussed is ZNF300; the disease is acute myeloid leukemia.